Drug survival of biologic therapies for the treatment of psoriasis: Results of Slovenian national registry

The study was designed as observational retrospective analysis of the data from Slovenian Registry of patients with moderate and severe psoriasis treated with adalimumab, etanercept, infliximab or ustekinumab from 2005 to 2015. The survival rates of biologics were compared using survival analysis, a...

Full description

Bibliographic details

Volume:	54
Main Author:	Lunder, Tomaz Marko, Pij Koser Kolar, Natasa Kralj, Boris Kecelj Leskovec, Nada
Format:	Journal Article
Language:	English
Place of publication:	LONDON Elsevier Ltd 01.07.2018 ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
published in:	Biologicals Vol. 54; pp. 44 - 49
Data of publication:	July 2018
ISSN:	1045-1056 1095-8320
EISSN:	1095-8320
Discipline:	Biology
Subjects:	Effectiveness Psoriasis Drug survival Risk factors Biologic therapy Pharmacology & Pharmacy Biochemistry & Molecular Biology Life Sciences & Biomedicine Biotechnology & Applied Microbiology Biochemical Research Methods Science & Technology Psoriasis - mortality Biological Therapy Psoriasis - drug therapy Age Factors Humans Middle Aged Male Survival Rate Disease-Free Survival Adult Anti-Inflammatory Agents - administration & dosage Female Registries Aged Retrospective Studies Slovenia Immunosuppressive Agents - administration & dosage Index Medicus Effectiveness Psoriasis Drug survival Risk factors Biologic therapy ADALIMUMAB RISK ARTHRITIS LONGITUDINAL ASSESSMENT PLAQUE PSORIASIS COHORT VULGARIS ETANERCEPT INFLIXIMAB BRITISH ASSOCIATION
Online Access:	available in Bonn?
Database:	Web of Knowledge Science Citation Index Expanded Web of Science - Science Citation Index Expanded - 2018 Web of Science MEDLINE (Ovid) PubMed MEDLINE MEDLINE MEDLINE Medline CrossRef MEDLINE - Academic Database information Databases - DBIS